Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales.

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy ...

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

Sanofi reported Q3 2024 sales growth of 15.7%, reaching 13.4 billion euros ($14.2 billion), with EPS up 12.2% to 2.86 euros.

The remaining 94,000 doses of state-funded influenza vaccine from a batch found with a discolored dose earlier this month ...

The FDA has approved updated labeling for Flublok (influenza vaccine) to include new safety data involving pregnant individuals.

Dr Yassir Javaid, a GP with a special interest in cardiology, explains the evidence to support the use of a high-dose ...

Birds and humans have different types of receptors in their respiratory tract that flu viruses attach to, like a lock (receptors) and key (virus). The attachment of the virus allows it to invade a ...

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

Key targets of the programme are elderly people and children. This programme is a part of Sanofi's commitment to improving ...

BEYFORTUS® Product Monograph, Sanofi Pasteur Limited, June 14, 2024. ii BEYFORTUS® Product Monograph, Sanofi Pasteur Limited, June 14, 2024. iii ...